Indivior PLC
INDV34.360USD
-0.090-0.26%
Close 02/06, 16:00（ET）Quotes delayed by 15 min
4.29BMarket Cap
34.93P/E TTM
More Details of Indivior PLC Company
Indivior PLC is a global pharmaceutical company engaged in developing medicines to treat substance-use disorders (SUD). The Company provides treatment for addiction, including SUBLOCADE (buprenorphine extended-release) injection for subcutaneous use, a long-acting injectable (LAI) for opioid use disorder and OPVEE (Nalmefene) nasal spray for opioid overdose recovery. Its core products include SUBOXONE Film, SUBOXONE Tablet, SUBUTEX Tablet, OPVEE (nalmefene), and SUBLOCADE. SUBOXONE Film is a buprenorphine and naloxone sublingual film. SUBOXONE Tablet is a buprenorphine and naloxone sublingual tablet. SUBUTEX Tablet is a buprenorphine sublingual tablet. SUBOXONE Film, SUBOXONE Tablet, SUBUTEX Tablet, and SUBLOCADE are treatments for opioid use disorder (OUD). In addition to its commercially available products, its product pipeline includes two drug candidates for the treatment of OUD. The Company sells its products in the United States and in other selected areas of the world.
Indivior PLC Info
Ticker SymbolINDV
Company nameIndivior PLC
IPO dateDec 24, 2014
CEOCiaffoni (Joseph J)
Number of employees1030
Security typeOrdinary Share
Fiscal year-endDec 24
Address234 Bath Road
CitySLOUGH
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited Kingdom
Postal codeSL1 4EE
Phone448043791090
Websitehttps://www.indivior.com/en
Ticker SymbolINDV
IPO dateDec 24, 2014
CEOCiaffoni (Joseph J)
Company Executives of Indivior PLC
Name
Name/Position
Position
Shareholding
Change
Mr. Christian Heidbreder
Mr. Christian Heidbreder
Chief Scientific Officer
Chief Scientific Officer
157.14K
+157140.00%
Mr. Vishal Kalia
Mr. Vishal Kalia
Chief Impact and Strategy Officer
Chief Impact and Strategy Officer
137.46K
+4329.00%
Mr. Joseph J. (Joe) Ciaffoni
Mr. Joseph J. (Joe) Ciaffoni
Chief Executive Officer, Director
Chief Executive Officer, Director
56.00K
--
Mr. Daniel A. (Dan) Ninivaggi, J.D.
Mr. Daniel A. (Dan) Ninivaggi, J.D.
Non-Executive Independent Director
Non-Executive Independent Director
15.78K
+775.00%
Ms. Juliet Thompson
Ms. Juliet Thompson
Senior Non-Executive Independent Director
Senior Non-Executive Independent Director
9.63K
+5775.00%
Dr. Keith Humphreys
Dr. Keith Humphreys
Non-Executive Independent Director
Non-Executive Independent Director
3.15K
-725.00%
Mr. Jeffrey W. (Jeff) Burris, Esq., J.D.
Mr. Jeffrey W. (Jeff) Burris, Esq., J.D.
Chief Legal Officer
Chief Legal Officer
760.00
--
Ms. Kathryn Barbara Hudson
Ms. Kathryn Barbara Hudson
Company Secretary
Company Secretary
--
--
Ms. Cynthia (Cindy) Cetani
Ms. Cynthia (Cindy) Cetani
Chief Integrity and Compliance Officer
Chief Integrity and Compliance Officer
--
--
Mr. Mark P. Stejbach
Mr. Mark P. Stejbach
Non-Executive Independent Director
Non-Executive Independent Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Christian Heidbreder
Mr. Christian Heidbreder
Chief Scientific Officer
Chief Scientific Officer
157.14K
+157140.00%
Mr. Vishal Kalia
Mr. Vishal Kalia
Chief Impact and Strategy Officer
Chief Impact and Strategy Officer
137.46K
+4329.00%
Mr. Joseph J. (Joe) Ciaffoni
Mr. Joseph J. (Joe) Ciaffoni
Chief Executive Officer, Director
Chief Executive Officer, Director
56.00K
--
Mr. Daniel A. (Dan) Ninivaggi, J.D.
Mr. Daniel A. (Dan) Ninivaggi, J.D.
Non-Executive Independent Director
Non-Executive Independent Director
15.78K
+775.00%
Ms. Juliet Thompson
Ms. Juliet Thompson
Senior Non-Executive Independent Director
Senior Non-Executive Independent Director
9.63K
+5775.00%
Dr. Keith Humphreys
Dr. Keith Humphreys
Non-Executive Independent Director
Non-Executive Independent Director
3.15K
-725.00%
Revenue Breakdown
Currency: USDUpdated: Tue, Jan 6
Currency: USDUpdated: Tue, Jan 6
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
Relevant data have not been disclosed by the company yet.
By RegionUSD
Name
Revenue
Proportion
United States
267.00M
85.03%
Rest of World
47.00M
14.97%
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Thu, Dec 4
Updated: Thu, Dec 4
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
BlackRock Institutional Trust Company, N.A.
6.24%
Oaktree Capital Management, L.P.
5.69%
Madison Avenue Partners LP
5.18%
Goldman Sachs & Company, Inc.
5.13%
Two Seas Capital LP
4.98%
Other
72.78%
Shareholders
Shareholders
Proportion
BlackRock Institutional Trust Company, N.A.
6.24%
Oaktree Capital Management, L.P.
5.69%
Madison Avenue Partners LP
5.18%
Goldman Sachs & Company, Inc.
5.13%
Two Seas Capital LP
4.98%
Other
72.78%
Shareholder Types
Shareholders
Proportion
Hedge Fund
33.03%
Investment Advisor/Hedge Fund
26.95%
Investment Advisor
13.84%
Research Firm
11.85%
Individual Investor
3.74%
Pension Fund
0.64%
Bank and Trust
0.31%
Family Office
0.27%
Other
9.37%
Institutional Shareholding
Updated: Thu, Jan 1
Updated: Thu, Jan 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
1
2.06K
0.00%
--
2025Q3
372
118.02M
94.53%
+2.51M
2025Q2
354
123.13M
98.21%
+4.02M
2025Q1
380
119.99M
96.15%
-1.70M
2024Q4
382
116.83M
93.64%
-10.43M
2024Q3
369
117.73M
91.72%
-15.91M
2024Q2
352
119.29M
90.10%
-8.99M
2024Q1
341
129.79M
96.57%
+3.79M
2023Q4
322
124.43M
92.28%
+2.93M
2023Q3
321
114.40M
84.40%
+17.06M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
BlackRock Institutional Trust Company, N.A.
7.79M
6.24%
+2.75M
+54.61%
Sep 30, 2025
Oaktree Capital Management, L.P.
7.11M
5.69%
-1.64M
-18.71%
Dec 24, 2025
Madison Avenue Partners LP
6.46M
5.18%
-1.46M
-18.41%
Sep 30, 2025
Goldman Sachs & Company, Inc.
6.41M
5.13%
+5.95M
+1302.98%
Sep 30, 2025
Two Seas Capital LP
6.21M
4.98%
-3.04M
-32.87%
Dec 23, 2025
Morgan Stanley & Co. LLC
5.58M
4.47%
+5.04M
+934.24%
Sep 30, 2025
Deerfield Management Company, L.P.
4.61M
3.7%
-2.37M
-33.95%
Nov 10, 2025
Newtyn Management, LLC
4.20M
3.36%
+1.59M
+61.10%
Sep 30, 2025
The Vanguard Group, Inc.
3.44M
2.76%
-2.18M
-38.82%
Sep 30, 2025
Sirovich (Matthew I.)
3.42M
2.74%
+249.62K
+7.87%
Sep 30, 2024
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
Lattice Hartford Multifactor Small Cap ETF
1.11%
ProShares Ultra Nasdaq Biotechnology
0.51%
Federated Hermes MDT Small Cap Core ETF
0.47%
Janus Henderson Small Cap Growth Alpha ETF
0.43%
First Trust Multi-Manager Small Cap Opportunities ETF
0.38%
Invesco Nasdaq Biotechnology ETF
0.36%
Franklin US Small Cap Multifactor Index ETF
0.32%
First Trust Active Factor Small Cap ETF
0.31%
Vanguard US Multifactor ETF
0.27%
Pacer US Small Cap Cash Cows ETF
0.26%
View more
Lattice Hartford Multifactor Small Cap ETF
Proportion1.11%
ProShares Ultra Nasdaq Biotechnology
Proportion0.51%
Federated Hermes MDT Small Cap Core ETF
Proportion0.47%
Janus Henderson Small Cap Growth Alpha ETF
Proportion0.43%
First Trust Multi-Manager Small Cap Opportunities ETF
Proportion0.38%
Invesco Nasdaq Biotechnology ETF
Proportion0.36%
Franklin US Small Cap Multifactor Index ETF
Proportion0.32%
First Trust Active Factor Small Cap ETF
Proportion0.31%
Vanguard US Multifactor ETF
Proportion0.27%
Pacer US Small Cap Cash Cows ETF
Proportion0.26%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Splits
Date
Ex-dividend Date
Type
Ratio
No Data
Date
Ex-dividend Date
Type
Ratio
No Data
